Rimidi develops clinical management platforms for optimizing workflows, enhance patient experiences and hit objectives for chronic disease management. Together, the companies aim to develop the Eversense remote patient monitoring (RPM) program for use by healthcare providers.
Senseonics develops the Eversense long-term, implantable continuous glucose monitor (CGM). Eversense, the longest-lasting CGM available, offers six months of wear time and only one insertion. It offers accuracy in critical low glucose ranges and essentially no compression lows. The system also has alert detection to support accurate corrections in real time.
Last week, the FDA granted Eversense integrated CGM designation. That designation allows it to connect with insulin pumps as part of an automated insulin delivery system.
On the back of that good news, the company now expects its RPM program to launch in select systems by the third quarter of 2024. With its commercial partner, Ascensia Diabetes Care, Sensonics plans for an expansion to all prescribers and users thereafter.
“The Eversense RPM Program is the next step in our roadmap to combine long-term implantable CGM technology with advanced analytics and personalized health services into a comprehensive diabetes solution. Eversense RPM will arm providers with powerful data to optimize care in between office visits where 99% of diabetes management takes place,” said Tim Goodnow, president and CEO of Senseonics. “Rimidi’s best-in-class platform will seamlessly integrate Eversense data. Combined with expert diabetes nurse counselors, proprietary decision support protocols, and fully compliant RPM reimbursement infrastructure, our Eversense CGM+RPM solution is intended to further differentiate Eversense from other CGM manufacturers, reaching beyond a stand-alone device and putting a comprehensive solution into the hands of health care systems, providers, and patients.
More about Rimidi and the partnership with Senseonics
The partnership integrates Eversense glucose data into Rimidi’s comprehensive clinical management platform. Rimidi’s platform aligns with Medicare’s reimbursable RPM telehealth programs and integrates within existing EHR systems.
According to the companies, this supports quality improvement initiatives and drives workflow optimization. It also increases patient engagement and provides clinical decision support.
Eversense CGM plus RPM, powered by Rimidi, could seamlessly and securely push glucose data to widely used EHR systems. That would provide direct access for providers and increase visibility on a number of metrics. Those metrics include glucose trends, high or low event frequency and time-in-range statistics.
With this data, providers can proactively engage patients to provide lifestyle and therapy optimization guidance to manage diabetes. Other benefits could include lowered healthcare costs and improved clinical outcomes.
“We are excited to combine our clinical management platform with Senseonics’ technology. Our platform and its capabilities were designed to leverage the data from medical devices like Eversense CGM to streamline and improve chronic disease management,” said Dr. Lucienne Ide, CEO of Rimidi. “81% of patients with type 2 diabetes do not meet their HbA1c, blood pressure and cholesterol goals, and this partnership represents an exciting opportunity to assist providers in driving improved glucose outcomes for this population.”
